Skip to main content

Wilserdly (giredestrant)

Wilserdly (giredestrant) is an oral, potent, next-generation, selective oestrogen receptor degrader (SERD) used for the treatment of adults with oestrogen receptor (ER)-positive, ESR1-mutated locally advanced or metastatic breast cancer. As a full antagonist it blocks oestrogen from binding to the ER, triggering the breakdown of the ER protein (known as degradation) and stopping or slowing down the growth of cancer cells.

In combination with everolimus, Wilserdly targets both ER signalling and the PI3K/AKT/mTOR pathway, two important mechanisms implicated in treatment resistance in ER-positive breast cancer.

Wilserdly, in combination with everolimus, is approved in the United States for the treatment of adults with ER-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by a Food and Drug Administration-authorised test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

SolutionsPharma Products
See all Pharma Products, Pharma Products
Product image - Wilserdly